In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites
about
Diabetes and gastric cancer: the potential linksUse of Insulin Lispro Protamine Suspension in PregnancyThe metabolic and mitogenic properties of basal insulin analoguesThe evolution of insulin glargine and its continuing contribution to diabetes careDevelopment of a human breast-cancer derived cell line stably expressing a bioluminescence resonance energy transfer (BRET)-based phosphatidyl inositol-3 phosphate (PIP3) biosensorEffect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2Molecular characterisation of long-acting insulin analogues in comparison with human insulin, IGF-1 and insulin X10Systematic evaluation of the metabolic to mitogenic potency ratio for B10-substituted insulin analoguesEngineering of insulin receptor isoform-selective insulin analoguesPharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance.A framework for the in vitro evaluation of cancer-relevant molecular characteristics and mitogenic potency of insulin analogues.Insulin analogs and cancer: a note of caution.Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml.Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes.Associations between diabetes medication use and risk of second breast cancer events and mortalityAlternative signaling network activation through different insulin receptor family members caused by pro-mitogenic antidiabetic insulin analogues in human mammary epithelial cellsInsulin glargine: a reevaluation of rodent carcinogenicity findings.Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence.Insulin analogs and cancer.The insulin receptor: a new target for cancer therapy.Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during PregnancyInsulin therapy and cancer in type 2 diabetes.Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetesGlargine and cancer: can we now suggest closure?Long-acting basal insulin analogs: latest developments and clinical usefulness.Looking at the carcinogenicity of human insulin analogues via the intrinsic disorder prism.Interpreting adverse signals in diabetes drug development programs.Differences in metabolic and mitogenic signallingof insulin glargine and AspB10 human insulin in rats [corrected].Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and igf-I receptor signaling.Treatment with insulin analogs, especially Glargine and Lispro, associates with better renal function and higher hemoglobin levels in Type 1 diabetic patients with impaired kidney function.Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF-I receptor.Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin.Insulin therapy and cancer.A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations.Insulin X10 revisited: a super-mitogenic insulin analogue.Insulin therapy in diabetes and cancer risk: current understanding and implications for future study: proceedings from a meeting of a European Insulin Safety Consensus Panel, convened and sponsored by Novo Nordisk, held Tuesday October 5, 2010 at ThMetabolism of biologics: biotherapeutic proteins.Insulin and GH-IGF-I axis: endocrine pacer or endocrine disruptor?Differences in bioactivity between human insulin and insulin analogues approved for therapeutic use- compilation of reports from the past 20 years.Insulin glargine metabolite 21(A) -Gly-human insulin (M1) is the principal component circulating in the plasma of young children with type 1 diabetes: results from the PRESCHOOL study.
P2860
Q24602836-4265254E-E42B-4CA2-91A1-265DA34EAFA1Q26779412-DA5C610C-3CBA-4342-95CA-DBF8D80FB6FFQ26991486-3E542D72-DB5B-4C0C-9B7E-1A31B833C108Q26999454-BB8505A9-2A12-4780-8888-BBD5EEADB0D2Q28541161-2AF5ACC5-000B-4EFB-835D-D02EE5DC3229Q28728738-C1FF7050-823D-4075-8CCE-7F1F2F78A5B3Q28730070-C9CDEB81-F3DF-4B9B-BAB6-54B10AFA1855Q28731843-20A4D4A2-C6B7-4B55-BDC1-6ACEDE980CA9Q28744380-248311EA-0F6F-4ADA-A7B8-2280D7467BA2Q30248803-A8D7CF89-D12B-43D1-A5A9-D8BB3C0DFADEQ30662831-9B9C44B8-3AB1-4B41-89EF-C0CE12FD1B25Q33660524-19DFFDCF-BBAF-4367-B558-48059FF4CEDBQ34543063-0BEB5A23-1D04-4732-8F55-B821D24194D5Q35044151-6B22FC28-CB6D-4512-B1CD-C852DB902777Q35850213-0E01533D-E4DB-4EF8-A0D0-B064D34891F4Q35863765-FB1D114D-134F-4B3E-94C6-48B68F79F999Q35886868-2EC37546-2B7B-4F7A-AF2E-6F4FF7D1A2D3Q35937961-CDBD09D3-DF6F-4AD0-905C-2BA98DA8C28EQ35971416-38E18056-902C-4B2C-B418-15898ADA397FQ35972002-FAECD776-0F32-4E67-A8A4-AECB0E5E60FEQ35996906-FDEF4C17-AB3A-4265-BF40-CA3A642D66D4Q36417868-2039AC17-2D73-4591-AC6F-05C60CE4C238Q36426750-55CBB067-A918-419A-9FB4-D77C76EBAEFEQ36426885-0F6814B8-CD84-4896-B8DC-ADA0DE52C6F7Q36515474-720202AA-3644-4842-8688-9348F53C6D67Q36694319-7A501616-4777-4D6F-8D45-B97068B81881Q36942266-648694C8-3925-4290-BEF2-9D49CCF1F752Q36976992-D960DECC-82C5-48AA-8EA5-BADCA10AA483Q37014889-1B5DDD2F-2B2B-40B3-B288-C37B20D40F78Q37151682-8BE3F7EF-022A-43FC-B909-BD3338F6B745Q37193406-2C1AC2ED-4A1B-47B0-91FF-F5731C72489DQ37278227-DD7E92D3-B6A6-4EEA-9332-7D060CC4646DQ37577175-38E763A7-28DF-4C92-80FE-5D202D53F6C6Q37853658-C2F2AD57-15B7-42E9-804A-BBE6F0A9625FQ37883970-0FA7779A-1654-4DCB-88C4-42462833C2E5Q37921639-A1A94D9B-7C29-45E8-9EF7-FEEA9A72635BQ37976442-AA5E704A-CDF7-42E1-ACAB-0173CA6B014AQ38239532-9EB147C4-591A-4964-BDB5-D351C9681C9AQ38255407-D05AA1E5-EEA7-46AC-B246-9BCD08EC3D86Q38426608-5ED25C15-D974-4AB2-8C3E-3CCCB5C0B956
P2860
In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites
@ast
In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites
@en
In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites.
@nl
type
label
In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites
@ast
In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites
@en
In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites.
@nl
prefLabel
In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites
@ast
In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites
@en
In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites.
@nl
P2093
P2860
P1433
P1476
In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites
@en
P2093
Georg Tschank
Gerhard Seipke
Mark R Sommerfeld
Norbert Tennagels
Paul Habermann
Roland Kurrle
P2860
P356
10.1371/JOURNAL.PONE.0009540
P407
P577
2010-03-04T00:00:00Z